New Sales License is a Key Development for FSD Pharma

The granting of the sales license allows FSD to serve the growing medicinal user market in Canada

FSD Pharma is focused on the development of high quality indoor grown, pharmaceutical grade cannabis. In addition, they focus on research and development of novel cannabinoid-based treatments for several central nervous system disorders. This includes chronic pain, fibromyalgia and irritable bowel syndrome

One of the most exciting milestones this year for FSD Pharma has been receiving their sales license. To further explain, they can now sell dried flower to prescription based consumers in Canada and in other parts of the world.

Now, FSD has begun to post revenues and that is an exciting development. They have a cultivation license, a processing license and now a sales license through thier acquisition of Prismatic Pharmaceuticals.

More on Prismatic Pharmaceuticals

Prismic was founded by three healthcare industry veterans, Zachary Dutton, Danilo Casadei Massari, and Peter Moriarty, who was also one of the founders of Shire Pharmaceuticals.

Moreover, Prismic is a US-based specialty pharmaceutical company dedicated to addressing the opioid crisis by developing novel non-addictive prescription drugs.

For more information on FSD Pharma (HUGE:CSE) please fill out the form below

Request Investor Kit